(MedPage Today) — BERLIN — Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic triple-negative breast cancer (TNBC) ineligible for immunotherapy, according to two randomized trials…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118038
Author :
Publish date : 2025-10-20 17:55:00
Copyright for syndicated content belongs to the linked Source.
